Experts thinks Biogen to likely be able to market Tecfidera in EU, says Leerink

theflyonthewall.com

Leerink Swann reports that experts expect Biogen's Tecfidera drug to be made available in the EU, as the experts report that patients there are very eager to obtain the drug The firm raised its price target on the stock to $300 from $286 and keeps an Outperform rating on the shares.

Rates

View Comments (0)